4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4.8800

14-February-25 16:45:00

15 minutes delayed

Stocks

+0.1600

+3.39%

Today's range

4.7900 - 5.4200

ISIN

N/A

Source

NASDAQ

4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer

07 Jun 2021 07:00:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

03 Jun 2021 07:00:01 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights

13 May 2021 16:03:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

12 May 2021 17:30:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform

04 May 2021 16:02:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

30 Apr 2021 07:05:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

27 Apr 2021 16:31:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights

25 Mar 2021 16:02:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease

09 Mar 2021 08:03:00 By Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.